eCite Digital Repository

Integrated guidance for enhancing the care of Familial Hypercholesterolaemia in Australia

Citation

Watts, GF and Sullivan, DR and Hare, DL and Kostner, KM and Horton, AE and Bell, DA and Brett, T and Trent, RJ and Poplawski, NK and Martin, AC and Justo, RN and Chow, CK and Pang, J and Radford, J, FH Australasia Network Consensus Working Group, Integrated guidance for enhancing the care of Familial Hypercholesterolaemia in Australia, Heart, Lung and Circulation, 30, (3) pp. 324-349. ISSN 1443-9506 (2021) [Substantial Review]


Preview
PDF
Pending copyright assessment - Request a copy
868Kb
  

DOI: doi:10.1016/j.hlc.2020.09.943

Abstract

Familial hypercholesterolaemia (FH) is a dominant and highly penetrant monogenic disorder present from birth that markedly elevates plasma low-density lipoprotein (LDL)-cholesterol concentration and, if untreated, leads to premature atherosclerosis and coronary artery disease (CAD). There are approximately 100,000 people with FH in Australia. However, an overwhelming majority of those affected remain undetected and inadequately treated, consistent with FH being a leading challenge for public health genomics. To further address the unmet need, we provide an updated guidance, presented as a series of systematically collated recommendations, on the care of patients and families with FH. These recommendations have been informed by an exponential growth in published works and new evidence over the last 5 years and are compatible with a contemporary global call to action on FH. Recommendations are given on the detection, diagnosis, assessment and management of FH in adults and children. Recommendations are also made on genetic testing and risk notification of biological relatives who should undergo cascade testing for FH. Guidance on management is based on the concepts of risk re-stratification, adherence to heart healthy lifestyles, treatment of non-cholesterol risk factors, and safe and appropriate use of LDL-cholesterol lowering therapies, including statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein apheresis. Broad recommendations are also provided for the organisation and development of health care services. Recommendations on best practice need to be underpinned by good clinical judgment and shared decision making with patients and families. Models of care for FH need to be adapted to local and regional health care needs and available resources. A comprehensive and realistic implementation strategy, informed by further research, including assessments of cost-benefit, will be required to ensure that this new guidance benefits all Australian families with or at risk of FH.

Item Details

Item Type:Substantial Review
Keywords:Familial Hypercholesterolaemia, preventive healthcare, atherosclerotic cardiovascular disease, genetic disease, screening, treatment
Research Division:Biomedical and Clinical Sciences
Research Group:Cardiovascular medicine and haematology
Research Field:Cardiology (incl. cardiovascular diseases)
Objective Division:Health
Objective Group:Clinical health
Objective Field:Diagnosis of human diseases and conditions
UTAS Author:Radford, J (Associate Professor Jan Radford)
ID Code:144244
Year Published:2021
Funding Support:National Health and Medical Research Council (GNT1142883)
Web of Science® Times Cited:9
Deposited By:Medicine
Deposited On:2021-05-04
Last Modified:2021-05-27
Downloads:0

Repository Staff Only: item control page